MindWalk is a Bio-Native AI company transforming drug discovery and development. MindWalk, formerly known as ImmunoPrecise Antibodies Ltd., is based in AUSTIN, Texas.
| Revenue (Most Recent Fiscal Year) | $17.59M |
| Net Income (Most Recent Fiscal Year) | $-21.69M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 6.59 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.49 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -166.92% |
| Net Margin (Trailing 12 Months) | -145.58% |
| Return on Equity (Trailing 12 Months) | -56.75% |
| Return on Assets (Trailing 12 Months) | -31.55% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.18 |
| Inventory Turnover (Trailing 12 Months) | 6.66 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.05 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.65 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.60 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 46.16M |
| Free Float | 43.00M |
| Market Capitalization | $95.55M |
| Average Volume (Last 20 Days) | 0.57M |
| Beta (Past 60 Months) | 0.48 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.83% |
| Percentage Held By Institutions (Latest 13F Reports) | 6.70% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |